A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Nantong Tumor Hospital
Nantong, Jiangsu, China
- Taizhou People'S Hospital
Taizhou, Jiangsu, China
- Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
- the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
- Huashan Hospital Affiliated To Fudan University
Shanghai, Shanghai Municipality, China
- Shanghai Sixth People'S Hospital
Shanghai, Shanghai Municipality, China
- Shanghai Tenth People'S Hospital
Shanghai, Shanghai Municipality, China
- Tongren Hospital Affiliated To Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
- Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
- Zhejiang Provincial People'S Hospital
Hangzhou, Zhejiang, China
- S.P Medical College & Ag Hospitals, Bikaner
Bīkaner, Dimhans, India
- Kiran Multi Super Speciality Hospital & Research Center
Surat, Gujarat, India
- Kailash Cancer Hospital and Research Center
Vadodara, Gujarat, India
- Aadhar Health Institute
Hisar, Haryana, India
- Noble Hospital, Pune
Hisar, Haryana, India
- Oncoville Cancer Hospital and Research Center
Bangalore, Karnataka, India
- Mumbai Oncocare Centre
Mumbai, Maharashtra, India
- Hcg Manavata Cancer Centre, Nashik
Naka, Nashik, India
- Western Regional Medical Center
Goodyear, Arizona, United States
- Innovative Clinical Research Institute
Whittier, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- Yale University - Hospital
New Haven, Connecticut, United States
- Ap Medical Research
Miami, Florida, United States
- Northwestern University - Hospital
Chicago, Illinois, United States
- University of Louisville - Hospital
Louisville, Kentucky, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Innovative Clinical Research Institute
Henderson, Nevada, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Montefiore Einstein Center for Cancer Care
The Bronx, New York, United States
- Gabrail Cancer Centre
Canton, Ohio, United States
- Ohio State University Dermatology
Columbus, Ohio, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Dec 2019
- Primary completion
- 26 Feb 2024
- Completion
- 30 Jun 2024
- Last update posted
- 4 Mar 2024
- Registered enrollment
- 170
- Registry id
- NCT04088318
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.